

Chemistry Letters

Palladium-catalyzed tandem synthesis of 2-aminobenzothiazoles starting from unreactive 2-chloroanilines

Wan Xu, Meng-Tian Zeng, Min Liu, Xing Liu, Cai-Zhu Chang, Hui Zhu,
Yue-Sheng Li, and Zhi-Bing Dong*

Advance Publication on the web February 18, 2017

doi:10.1246/cl.170023

© 2017 The Chemical Society of Japan

Advance Publication is a service for online publication of manuscripts prior to releasing fully edited, printed versions. Entire manuscripts and a portion of the graphical abstract can be released on the web as soon as the submission is accepted. Note that the Chemical Society of Japan bears no responsibility for issues resulting from the use of information taken from unedited, Advance Publication manuscripts.

Palladium-catalyzed tandem synthesis of 2-aminobenzothiazoles starting from unreactive 2-chloroanilines

Wan Xu^a, Meng-Tian Zeng^a, Min Liu^a, Xing Liu^a, Cai-Zhu Chang^a, Hui Zhu^a, Yue-Sheng Li^c and Zhi-Bing Dong^{*a,b}

^aSchool of Chemistry and Environmental Engineering, Wuhan Institute of Technology, Wuhan 430074, China

^bKey Laboratory of Green Chemical Process, Ministry of Education, Wuhan Institute of Technology, Wuhan 430074, China

^cNon-power Nuclear Technology Collaborative Innovation Center, Hubei University of Science & Technology, Xianning 437100, China

E-mail: zhibingdong80@aliyun.com

A simple and efficient protocol for the synthesis of 2-aminobenzothiazole derivatives is described. 2-Chloroanilines were treated with thiocarbamoyl chloride in the presence of Pd(dba)₂ and *t*-BuOK to afford the corresponding 2-aminobenzothiazoles in good to excellent yield *via* a tandem manner.

Heterocycles, that most ubiquitous structural motifs, are existing in natural products and therapeutics^[1-3]. Benzothiazole is an important constituent of various drugs and shows fundamental potential application in the development of novel therapeutics^[4-5]. For example, riluzole (**a**) is used as treatment of amyotrophic lateral serotonin^[6], R116010 (**b**) exhibits as an anticancer drug^[7] and 2-aminobenzothiazole (**c**) acts as anti-HIV agent^[8] (**Fig. 1**).




Fig. 1 Examples of bioactive 2-aminobenzothiazoles

The development of efficient methods for the synthesis of benzothiazoles has received considerable attention. Over the last few decades, a wide range of synthetic methods have been developed giving access to benzothiazoles bearing various functionalities. Among the synthetic strategies, a series of transition metal catalyzed reaction were explored to construct benzothiazoles such as Pd^[10], Cu^[11], Fe^[12] and Ag^[13]. To the best of our knowledge, there are few reports for the synthesis of benzothiazoles using 2-chloroanilines as starting materials due to the low reactivity of the C-Cl bond, and the reported methods suffer from either long reaction time or low yield^[14]. Herein, we present a facile and efficient protocol for the synthesis of 2-aminobenzothiazoles utilizing functionalized 2-chloroanilines in the presence of palladium catalyst.

For our initial studies, 2-chloroaniline (**1a**) and dimethylthiocarbamoyl chloride (**1b**) were investigated under various conditions (**Table 1**). For the catalyst screening, Fe(OAc)₃, NiCl₂, CuBr, Cu(OTf)₂, PdCl₂, Pd(OAc)₂, and PdBr₂ were tested, but they led to no product formation (**Table 1, entries 1-7**). Gratifyingly other catalysts, such as Pd(PPh₃)₄ and Pd(dba)₂, provided the desired product in good yields

(**entries 8-9**). The effect of additive was further evaluated (**entries 10-14**), and the results indicated that *t*-BuOK is superior than other bases. Solvents, temperature and the base quantity were further investigated. The transform was conducted in various solvents (DMAC, DMF, DMSO, toluene and acetonitrile) but afforded the 2-aminobenzothiazole in poor to moderate yield (**entries 15-19**). When the reaction was operated under 40 °C or room temperature, it led to poor reactivity (**entries 20-21**). The excess of *t*-BuOK was proved crucial for full conversion. When one or two equivalent of base was used giving lower yield or no product formation (**entry 22-23**).

Table 1. Screening reaction conditions for 2-chloroaniline and dimethylthiocarbamoyl chloride^a.

Entry	Catalyst	Base (equiv)	Solvent	Temp (°C)	Yield ^b (%)
1	Fe(OAc) ₃	<i>t</i> -BuOK (3.0)	THF	60	-
2	NiCl ₂	<i>t</i> -BuOK (3.0)	THF	60	-
3	CuBr	<i>t</i> -BuOK (3.0)	THF	60	-
4	Cu(OTf) ₂	<i>t</i> -BuOK (3.0)	THF	60	-
5	PdCl ₂	<i>t</i> -BuOK (3.0)	THF	60	-
6	Pd(OAc) ₂	<i>t</i> -BuOK (3.0)	THF	60	-
7	PdBr ₂	<i>t</i> -BuOK (3.0)	THF	60	-
8	Pd(PPh ₃) ₄	<i>t</i> -BuOK (3.0)	THF	60	83
9	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	THF	60	91
10	Pd(dba) ₂	NaH (3.0)	THF	60	62
11	Pd(dba) ₂	K ₂ CO ₃ (3.0)	THF	60	54
12	Pd(dba) ₂	NEt ₃ (3.0)	THF	60	31
13	Pd(dba) ₂	CS ₂ CO ₃ (3.0)	THF	60	73
14	Pd(dba) ₂	CH ₃ ONa (3.0)	THF	60	67
15	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	DMAC	60	19
16	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	DMF	60	25
17	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	DMSO	60	53
18	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	PhCH ₃	60	65
19	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	CH ₃ CN	60	-
20	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	THF	40	69
21	Pd(dba) ₂	<i>t</i> -BuOK (3.0)	THF	rt	-
22	Pd(dba) ₂	<i>t</i> -BuOK (2.0)	THF	60	51
23	Pd(dba) ₂	<i>t</i> -BuOK (1.0)	THF	60	-

^a Reaction conditions: **1a** (1.0 mmol), **2a** (1.2 mmol), [Cat.] (5 mmol%) solvent (3.0 mL) for 3.5 h; ^b Isolated yield.

Under optimal conditions, various functionalized 2-chloroaniline derivatives and thiocarbamoyl chloride were converted to desired benzothiazoles as shown in **Table 2**. 2-Chloroanilines bearing a substitution at the 4-position tended to cyclize well with dimethylthiocarbamoyl chloride (**1b**) in 71-

90% yield (**entry 2-5**). When 5-substituted 2-chloroanilines were used, palladium mediated benzothiazole formation providing desired product **6c-8c** in 58-92% yield (**entry 6-8**). Subsequently, the thiocarbamoyl chloride **2b** was examined under the same condition and afforded corresponding product **9c** and **10c** in 84% and 82% yield, respectively.

Table 2. Palladium-catalyzed synthesis of substituted 2-aminobenzothiazoles^a.

$\text{R}_1\text{-C}_6\text{H}_3\text{(NH}_2\text{)(Cl)} + \text{Cl-C(=S)-N(R}_2\text{)}_2 \xrightarrow[\text{3-3.5 h}]{\text{Pd(dba)}_2, \text{t-BuOK, THF, 60 }^\circ\text{C}}$ $\text{R}_1\text{-C}_6\text{H}_3\text{(N(R}_2\text{)}_2\text{)(S)-C}_6\text{H}_4\text{}$				
Entry	2-Chloroaniline	Thiocarbamoyl chloride	Product	Yield ^b (%)
1				91
2				80
3				90
4				86
5				71
6				92
7				58
8				81
9				84
10				82

^a Reaction conditions: **1** (1.0 mmol), **2** (1.5 mmol), Pd(dba)₂ (5 mol%), t-BuOK (3.0 mmol), and THF (3 mL) at 60 °C; ^b Isolated yield.

As for the reaction mechanism, a tandem pathway is proposed. The first step is the base-promoted formation of aryl thioureas, the second one is the palladium-catalyzed intramolecular cross-coupling reaction which let the arylthioureas afford the 2-aminobenzothiazoles smoothly.

In conclusion, we present a useful protocol for the preparation of various substituted 2-aminobenzothiazoles starting from cheap 2-chloroaniline derivatives and thiocarbamoyl chloride. The broad substrate scope, short reaction time, mild react condition and good to excellent yield make this approach attractive. Further investigation on the

synthesis of various heterocyclic compounds is under research in our laboratory.

Acknowledgement

We thank the foundation support from National Natural Science Foundation of China (21302150, 11405050), Hubei Provincial Department of Education (D20131501), Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [2012]1707, President foundation of Wuhan Institute of Technology (2014038), foundation of Chutian distinguished fellow from Hubei Provincial Department of Education, foundation of High-end Talent Cultivation Program from Wuhan Institute of Technology. We also thank Prof. Aiwen Lei at Wuhan University for his generous NMR analysis support.

References and Notes

- [1] I. Yildiz-Oren, I. Yalcin, E. Aki-Sener, *Eur. J. Med. Chem.* **2004**, *39*, 291.
- [2] A. R. Katritzky, C.W. Rees, *Angew. Chem. Int. Ed.* **1985**, *24*, 1005.
- [3] G. P. Gunwardana, S. Kohmoto, S. P. Gunasekera, O. J. McConnell, F. E. Koehn, *J. Am. Chem. Soc.* **1988**, *110*, 4856.
- [4] a) V. Klimesova, J. Koci, K. Waisser, J. Kaustova, U. McIlmann, *Eur. J. Med. Chem.* **2009**, *44*, 2286. b) C. Sheng, H. Xu, W. Wang, Y. Cao, G. Dong, S. Wang, X. Che, H. Ji, Z. Miao, J. Yao, W. Zhang, *Eur. J. Med. Chem.* **2010**, *45*, 3531.
- [5] a) K. G. Liu, J. R. Lo, T. A. Comery, G. M. Zhang, J. Y. Zhang, D. M. Kowal, D. L. Smith, E. H. Kerns, L. E. Schechter, A. J. Robichaud, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1115. b) C. J. O'Donnell, B. N. Rogers, B. S. Bronk, D. K. Bryce, J. W. Coe, K. K. Cook, A. J. Duplantier, E. Evrard, M. Hajos, W. E. Hoffmann, R. S. Hurst, N. Maklad, R. J. Mather, S. McLean, F. M. Nedza, B. T. O'Neill, L. Peng, W. Qian, M. M. Rottas, S. B. Sands, A. W. Schmidt, A. V. Shrikhande, D. K. Spracklin, D. F. Wong, A. Zhang, L. J. Zhang, *J. Med. Chem.* **2010**, *53*, 1222.
- [6] a) M. E. McDonnell, M. D. Vera, B. E. Blass, J. C. Pelletier, R. C. King, C. F. Metzler, G. R. Smith, J. Wrobel, S. Chen, B. A. Wall, A. B. Reitz, *Bioorg. Med. Chem.* **2012**, *20*, 5642. b) B. C. Cheah, S. Vucic, A. V. Krishnan, M. C. Kiernan, *Curr. Med. Chem.* **2010**, *17*, 1942.
- [7] J. Van Heudsen, R. Van Ginckel, H. Bruwiere, P. Moelans, B. Janssen, W. Floren, B. J. Van der Leede, J. van Dun, G. Sanz, M. Venet, L. Dillen, C. Van Hove, G. Willemsens, M. Janicot, W. Wouters, *Br. J. Cancer.* **2002**, *86*, 605.
- [8] S. Massari, D. Daelemans, M. L. Barreca, A. Knezevich, S. Sabatini, V. Cecchetti, A. Marcello, C. Pannecouque, O. Tabarrini, *J. Med. Chem.* **2010**, *53*, 641.
- [9] a) C. W. Cheung, D. S. Surry, S. L. Buchwald, *Org. Lett.* **2013**, *15*, 14. b) L. L. Joyce, R. A. Batey, *Org. Lett.* **2009**, *11*, 13. c) S. Toulot, T. Heinrich, F. R. Leroux, *Adv. Synth. Catal.* **2013**, *355*, 3263.
- [10] a) D. Ma, X. Lu, L. Shi, H. Zhang, Y. Jiang, X. Liu, *Angew. Chem. Int. Ed.* **2011**, *50*, 1118. b) T. Kawano, K. Hirano, T. Satoh, M. Miura, *J. Am. Chem. Soc.* **2010**, *132*, 6900. c) X. Deng, H. McAllister, N. S. Mani, *J. Org. Chem.* **2009**, *74*, 5742. d) S. Guo, B. Qian, Y. Xie, C. Xia, H. Huang, *Org. Lett.* **2011**, *13*, 3. e) Y. Xie, B. Qian, P. Xie, H. Huang, *Adv. Synth. Catal.* **2013**, *35*, 1315. f) S. Chen, K. Zheng, F. Chen,

- Tetrahedron Lett.* **2012**, 53, 6297. g) S. S. Pi, X. G. Zhang, R.Y. Tang, J. H. Li, *synlett.* **2009**, 18, 3032.
- [11] J. Wang, J. Hou, J. Wen, J. Zhang, X. Yu, *Chem Commun.* **2011**, 47, 3652.
- [12] S. H. Cho, J. Y. Kim, S. Y. Lee, S. Chang, *Angew. Chem. Int. Ed.* **2009**, 48, 9127.
- [13] a) J. Zhao, H. Huang, W. Wu, H. Chen and H. Jiang, *J. Med. Chem.* **2010**, 53, 641. b) M. Lamani and K. R. Prabhu, *J. Org. Chem.* **2011**, 76, 7938. c) T. P. Petersen, A. F. Larsen, A. Ritz'en, T. Ulven, *J. Org. Chem.* **2013**, 78, 4190. d) A. I. Khalaf, R. G. Alvarez, C. J. Suckling, R. D. Waigh, *Tetrahedron*, **2000**, 56, 8567.
- [14] a) Y. J. Guo, R.Y. Tang, P. Zhong, J. H. Li, *Tetrahedron Lett.* **2010**, 51, 649. b) N. Khatun, L. Jamir, M. Ganesh, B. K. Patel, *RSC Advances*, **2012**, 2, 11557.